The grant strengthens Neogap’s international IP position and supports its long-term strategy to protect and advance its proprietary technologies globally, it states.

“Strong international IP protection is critical as we advance in clinical development – not only to enable future partnerships, but to reinforce the global credibility of our technology,” says Samuel Svensson, CEO of Neogap Therapeutics.

The Chinese patent covers a process used to produce Neogap’s personalised cell-based immunotherapy, pTTL, which is currently under evaluation in a Phase I/II clinical trial for advanced colorectal cancer.

Legal protection in China until 2038

This patent provides legal protection in China until 2038 and further strengthens Neogap’s international intellectual property portfolio in a strategically important market for advanced therapies.

It follows the grant of an equivalent patent in Europe in 2023, along with other IP approvals in Europe and other key markets, and the classification of pTTL as an Advanced Therapy Medicinal Product (ATMP) by the European Medicines Agency.

The patented method

The patented method enables the ex vivo expansion of tumour-specific T cells by exposing them to selected antigens, facilitating the production of therapeutic cell populations with improved tumour reactivity. The method forms part of Neogap’s proprietary EpiTCer technology, and has previously been granted patent protection in Europe.